GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

sibeprenlimab   Click here for help

GtoPdb Ligand ID: 12102

Synonyms: sibeprenlimab-szsi | VIS-649 | VIS649 | Voyxact®
Approved drug Immunopharmacology Ligand
sibeprenlimab is an approved drug
Compound class: Antibody
Comment: Sibeprenlimab (VIS-649) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13) [2,5]. The antibody binds with high affinity to human trimeric APRIL, and potently blocks APRIL binding to its receptors TACI (transmembrane activator and CAML interactor) and BCMA (B-cell maturation antigen). APRIL mediates antibody class switching in mature B cells and promotes plasma-cell survival. APRIL acts to elevate production of IgA and pathogenic galactose-deficient IgA1, by mediating class switching in mature B cells and promoting plasma-cell survival. Galactose-deficient IgA1 is a key driver of the IgA nephropathy pathology. Hence targeting APRIL is considered as a mechanism to reduce IgA-mediated kidney damage.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
APRIL Hs Antibody Binding 12.0 pKd - 5
⤷ pKd 12.0 (Kd 9.5x10-13 M) [5]
Description: Binding affinity determined by surface plasmon resonance (SPR)